Opthea Ltd (CKDXF)
Ceryvyn Therapeutics Ltd is a clinical-stage biopharmaceutical company developing therapies for the rare lung disease lymphangioleiomyomatosis (LAM). Its lead program, CYV-101, is a fusion protein designed to neutralize VEGF-C and VEGF-D, key signaling proteins involved in the disease. The company was formerly known as Opthea Limited.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Ceryvyn Therapeutics Ltd
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
AUCeryvyn Therapeutics Ltd is a clinical-stage biopharmaceutical company developing therapies for the rare lung disease lymphangioleiomyomatosis (LAM).
Its lead program, CYV-101, is a fusion protein designed to neutralize VEGF-C and VEGF-D, key signaling proteins involved in the disease.
The company was formerly known as Opthea Limited.
Leadership
Michael Gerometta
Chief Technology Officer
Jeremy Max Levin Ba Zoology Dphil Mb Bchir
Chief Executive Officer & Chairperson
Hamish George
Chief Financial Officer & Joint Company Secretary
Stephanie Vipond
Joint Company Secretary
Employees
--
Country
AU
Sector
Healthcare
Website
ceryvyn.com
| Name | Shares | % | Source |
|---|---|---|---|
Regal Partners Funds Management Pty Limited · joint filing· may incl. warrants· filed Jul 2026 | 45.2M | 3.3% | 13G |
AU30d Avg
5.46K
60d Avg
5.46K
90d Avg
5.46K